They found that most patients with IDH-WT grade 2 gliomas met the cIMPACT criteria because of isolated TERT promoter mutations that were not predictive of poor outcomes, hence, some caution is needed when assimilating IDH-WT grade 2 gliomas to molecular glioblastomas, especially those with isolated TERT promoter mutation [15]. The gene discussed is IDH1; the disease is glioblastoma.